LIGAND PHARMACEUTICALS

Ligand (LGND) stocks fell 2.21% to $303.24, still far below its 52‑week high. Despite a $6.3B cap and robust biotech pipeline, the price slide raises questions about strategy and investor confidence.

Ligand’s stock surges 5.5% as peers stagnate – with a strong pipeline, solid fundamentals, and attractive valuation for growth‑seeking investors.

Ligand (LGND) surges 3.07% as its $314.78 stock climbs toward a $326.63 52‑week high—see the latest 24‑hour market snapshot, trading volume and key company insights.